Finally, given that ongoing clinical trials specifically targeting TRPM4 have been approved in patients with stroke [126], it can be expected that, soon, other TRP-based therapeutic strategies may have an adequate safety profile and be applied in the field of cancer, including haematological malignancies. This evidence concerns the gene TRPM4 and Stroke.